On-Q-ity Sees CTC Test Value for Pharma Studies, PGx Efforts | GenomeWeb

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – With initial efforts aimed at bringing its circulating tumor cell platform to drug development researchers, On-Q-ity also has its sights set on the clinic, pharmacogenomics market, and detection of additional kinds of cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.